{"id":"rituximab-hds","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rituximab targets CD20, a surface antigen expressed on B lymphocytes, leading to B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. The HDS (high-dose schedule) variant uses intensified dosing to enhance therapeutic efficacy in lymphoid malignancies. This mechanism is particularly effective in B-cell non-Hodgkin lymphomas where CD20+ tumor cells are the primary target.","oneSentence":"Rituximab-HDS is a high-dose formulation of rituximab, a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:30.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma (various subtypes)"},{"name":"Lymphoid malignancies expressing CD20"}]},"trialDetails":[{"nctId":"NCT00801216","phase":"PHASE2","title":"High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement","status":"COMPLETED","sponsor":"Andrés José Maria Ferreri","startDate":"2007-01","conditions":"B-cell Lymphomas","enrollment":40},{"nctId":"NCT00355199","phase":"PHASE3","title":"Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.","status":"COMPLETED","sponsor":"Gruppo Italiano Terapie Innovative nei Linfomi","startDate":"2005-05","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":246}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rituximab supplemented high-dose sequential chemotherapy."],"phase":"phase_3","status":"active","brandName":"Rituximab-HDS","genericName":"Rituximab-HDS","companyName":"Gruppo Italiano Terapie Innovative nei Linfomi","companyId":"gruppo-italiano-terapie-innovative-nei-linfomi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab-HDS is a treatment for Diffuse Large B-Cell Lymphoma and B-cell Lymphomas, which involves binding to the B-lymphocyte antigen CD20. It is classified as a BINDING AGENT and functions as an antibody that targets CD20.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}